Unigene to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012

BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York, NY. Mr. Palmer's presentation is scheduled to begin at 11:00 a.m. ET on Monday, February 13, 2012.

Individuals can listen to a live webcast of the presentation by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[email protected]

Media Contact
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[email protected] / [email protected]

SOURCE Unigene Laboratories, Inc.